SCHEMBL1995733

SCHEMBL1995733

Cc1ccc(Nc2nc3ccccc3[nH]2)cc1C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 4/20 0.52
MAPT P10636 3/20 0.52
DDX3X O00571 1/20 0.50
AKR1C3 P42330 1/20 0.49
MTOR P42345 1/20 0.47
KDR P35968 2/20 0.47
TAS2R14 Q9NYV8 1/20 0.46
POLB P06746 1/20 0.46
PDE10A Q9Y233 2/20 0.45
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LCK P06239 1/20 0.44
MAPK14 Q16539 1/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1996070 0.86 MEN1 (0.55) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL2004020 0.85 MEN1 (0.53) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL1998478 0.85 KDR (0.63) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL1998057 0.80 MEN1 (0.57) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL1998129 0.78 MTOR (0.67) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL1998475 0.77 AKR1C3 (0.59) MEN1KMT2ADDX3XAKR1C3MTOR
SCHEMBL18418447 0.77 MEN1 (0.57) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL1999902 0.77 DYRK1A (0.53) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL1163657 0.77 MEN1 (0.56) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL6037544 0.76 MEN1 (0.71) MEN1KMT2ARAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US claimed
US-7960561-B2 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2011-06-14 US disclosed
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels KCNN2, KCNN1, KCNN3 MEN1 2186/4885KMT2A 1406/4885RAB9A 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.